On October 13, 2014 the Metastatic Breast Cancer Alliance revealed the results of an analysis that identified 169 new target therapies under development for the treatment of metastatic breast cancer, 71 of which are in Phase II or III of clinical trials. Marc Hurlbert, PhD, Executive Director of the Avon Foundation for Women calls the emerging therapies “a cautious but realistic hope,” in addition to identifying the unmet psychosocial needs of patients with breast cancer.